[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE138267T1 - Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen - Google Patents

Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen

Info

Publication number
ATE138267T1
ATE138267T1 AT91900131T AT91900131T ATE138267T1 AT E138267 T1 ATE138267 T1 AT E138267T1 AT 91900131 T AT91900131 T AT 91900131T AT 91900131 T AT91900131 T AT 91900131T AT E138267 T1 ATE138267 T1 AT E138267T1
Authority
AT
Austria
Prior art keywords
satellite cells
pct
cytokines
lif
alone
Prior art date
Application number
AT91900131T
Other languages
English (en)
Inventor
Lawrence Austin
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of ATE138267T1 publication Critical patent/ATE138267T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of El Displays (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
AT91900131T 1989-11-24 1990-11-20 Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen ATE138267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ755289 1989-11-24

Publications (1)

Publication Number Publication Date
ATE138267T1 true ATE138267T1 (de) 1996-06-15

Family

ID=3774381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91900131T ATE138267T1 (de) 1989-11-24 1990-11-20 Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen

Country Status (10)

Country Link
US (1) US5435999A (de)
EP (1) EP0502081B1 (de)
JP (2) JP3040815B2 (de)
AT (1) ATE138267T1 (de)
AU (1) AU624284B2 (de)
CA (1) CA2045630A1 (de)
DE (1) DE69027123T2 (de)
HK (1) HK1003475A1 (de)
NO (1) NO922008L (de)
WO (1) WO1991007992A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
DE69119759T2 (de) * 1990-03-20 1997-01-16 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
EP0620736B1 (de) * 1991-12-24 2001-03-07 Amrad Corporation Limited Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
WO1994021272A1 (en) * 1993-03-17 1994-09-29 Amrad Corporation Limited A method for treating microbial infection in an animal by administering a composition comprising lif and a cytokine
US20020164313A1 (en) * 1995-03-16 2002-11-07 Tremblay Jacques P. Compositions comprising preconditioned myoblasts having enhanced fusion properties
US5833978A (en) * 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
GB2301114A (en) * 1995-05-24 1996-11-27 Bradley Michael John Stringer Method for controlling differentiation of precursor cells
JPH11507047A (ja) * 1995-06-06 1999-06-22 ケース ウエスターン リザーブ ユニバーシティ ヒト間葉幹細胞の筋原性分化
EP0946713B1 (de) * 1996-10-18 2007-03-07 Universite Laval Verfahren zur in vitro vorbehandlung von myoblasten in der transplantation
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
DK1272204T3 (da) 2000-04-14 2007-09-10 Univ Pittsburgh Forstærkning og bulking af blödt væv og knoglevæv under anvendelse af muskelafledte progenitorceller, præparater deraf og behandling dermed
JP4680483B2 (ja) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
WO2004096245A2 (en) 2003-04-25 2004-11-11 The University Of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
GB2433122B (en) 2005-12-10 2008-07-23 Endet Ltd Gas sampling probe
EP2118271B1 (de) 2007-01-11 2018-04-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellen aus muskeln zur behandlung von harnwegserkrankungen sowie verfahren zu ihrer herstellung und verwendung
US9199003B2 (en) 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
WO2010031190A1 (en) * 2008-09-22 2010-03-25 UNIVERSITé LAVAL Culture medium for myoblasts, precursors thereof and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor
JP2740320B2 (ja) * 1988-08-04 1998-04-15 アムラド・コーポレイション・リミテッド 胚幹細胞のインビトロ増殖
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity

Also Published As

Publication number Publication date
DE69027123T2 (de) 1997-04-24
HK1003475A1 (en) 1998-10-30
NO922008D0 (no) 1992-05-21
EP0502081A4 (en) 1993-05-05
US5435999A (en) 1995-07-25
CA2045630A1 (en) 1991-05-25
JPH05502224A (ja) 1993-04-22
NO922008L (no) 1992-07-20
JP2000128791A (ja) 2000-05-09
DE69027123D1 (de) 1996-06-27
JP3040815B2 (ja) 2000-05-15
AU6896791A (en) 1991-06-26
EP0502081B1 (de) 1996-05-22
EP0502081A1 (de) 1992-09-09
WO1991007992A1 (en) 1991-06-13
AU624284B2 (en) 1992-06-04

Similar Documents

Publication Publication Date Title
ATE138267T1 (de) Proliferative wirkung des leukämie- hemmungsfaktors auf satellitzellen
Felix et al. Bone-resorbing cytokines enhance release of macrophage colony-stimulating activity by the osteoblastic cell MC3T3-E1
Moore et al. Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice.
Mayer et al. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons—i. Effectsin vitro
ES2001967A6 (es) Un metoo para producir una proteina a partir de un cultivo de celulas.
IL128129A (en) Uses for human wnt polypeptides
PH17834A (en) Homogenous human interleukin,pharmaceutical compositions containing the same and process therefor
DK546388A (da) Polypeptidvaekstfaktor fra maelk
IT8721005A0 (it) Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
CA2430112A1 (en) Paramyxovirus vector encoding angiogenesis gene and use thereof
HUT63769A (en) Process for producing pharmaceutical compositions comprising il-4 as active ingredient and suitable for treating thick tumours
US6423681B1 (en) Method of inducing formation of kidney epithelia from mesenchymal precursors
Nicolas et al. Effects of acidic fibroblast growth factor and epidermal growth factor on subconfluent fetal rat calvaria cell cultures: DNA synthesis and alkaline phosphatase activity
JO1677B1 (en) 3,3 'compounds - dithiobase (prepernic acid) and its organic salts
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
Sauder et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury
Karagenc et al. Soluble factors and the emergence of chick primordial germ cells in vitro
CA2017315A1 (en) Interleukin i inhibitor
HU9202026D0 (en) Method and medical preparative for treatment of thrombocytopenie
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells
DE3879575D1 (de) Alpha-carotin zur wachstumshemmung von krebszellen.
EP0620736A4 (en) A method for the treatment of tumours and sarcomas.
Carmeliet Interleukin-6 a putative mediator of anterior pituitary hormone secretion during the stress of infection?
Austin Proliferative action of leukaemia inhibitory factor on satellite cells
UA27048C2 (uk) Лікарський препарат імуhокоригуючої дії hа осhові клітиhhої суспеhзії, спосіб лікуваhhя цукрового діабету з використаhhям цього препарату

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties